Organon & Co. (OGN)

USD 11.52

(2.45%)

Operating Income Summary of Organon & Co.

  • Organon & Co.'s latest annual operating income in 2023 was 1.32 Billion USD , down -10.76% from previous year.
  • Organon & Co.'s latest quarterly operating income in 2024 Q1 was 414 Million USD , up 32.69% from previous quarter.
  • Organon & Co. reported an annual operating income of 1.47 Billion USD in 2022, down -8.71% from previous year.
  • Organon & Co. reported an annual operating income of 1.61 Billion USD in 2021, down -43.17% from previous year.
  • Organon & Co. reported a quarterly operating income of 386 Million USD for 2024 Q2, down -6.76% from previous quarter.
  • Organon & Co. reported a quarterly operating income of 414 Million USD for 2024 Q1, up 32.69% from previous quarter.

Annual Operating Income Chart of Organon & Co. (2023 - 2017)

Historical Annual Operating Income of Organon & Co. (2023 - 2017)

Year Operating Income Operating Income Growth
2023 1.32 Billion USD -10.76%
2022 1.47 Billion USD -8.71%
2021 1.61 Billion USD -43.17%
2020 2.84 Billion USD -25.94%
2019 3.84 Billion USD 42.17%
2018 2.7 Billion USD -17.3%
2017 3.27 Billion USD 0.0%

Peer Operating Income Comparison of Organon & Co.

Name Operating Income Operating Income Difference
AbbVie Inc. 12.75 Billion USD 89.582%
Bristol-Myers Squibb Company 16.59 Billion USD 91.993%
Bristol-Myers Squibb Company Ce 16.59 Billion USD 91.993%
Johnson & Johnson 23.4 Billion USD 94.323%
Eli Lilly and Company 10.32 Billion USD 87.129%
Merck & Co., Inc. 2.95 Billion USD 55.01%
Novartis AG 9.76 Billion USD 86.396%
Pfizer Inc. 3.35 Billion USD 60.435%